Completed PHASE2 INTERVENTIONAL 5-arm NCT00218413

Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals

A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers

Sponsor: Nabi Biopharmaceuticals

Conditions Smoking Cessation Tobacco Use Cessation

Interventions NicVAX

Updated 6 times since 2017 Last updated: Jan 11, 2017 Started: Oct 31, 2004 Primary completion: Aug 31, 2006 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Smoking Cessation and Tobacco Use Cessation, this trial is completed. The trial is conducted by Nabi Biopharmaceuticals and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nabi Biopharmaceuticals
National Institute on Drug Abuse (NIDA)

Data source: National Institute on Drug Abuse (NIDA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Maastricht, Netherlands